Clinical Trial

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Study acronym: exPDite-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
Protocol Amendment History 1 change
notable Trial sites expanded: 33 -> 37 locations 2026-04-02
Trial Details
NCT Number NCT06944522
Lead Sponsor BlueRock Therapeutics
Collaborators: Bayer
Conditions Parkinsons Disease (PD)
Enrollment 102 participants
Start Date 2025-06-17
Primary Completion 2027-03 (estimated)
Study Completion 2032-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-04